- Report
- November 2024
- 152 Pages
Global
From €4414EUR$4,650USD£3,724GBP
- Report
- August 2024
- 120 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- March 2025
- 349 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 175 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- December 2024
- 200 Pages
Global
From €3560EUR$3,750USD£3,003GBP
- Report
- September 2024
- 389 Pages
Global
From €3984EUR$4,197USD£3,361GBP
- Report
- September 2024
- 296 Pages
Global
From €3984EUR$4,197USD£3,361GBP
- Report
- December 2024
- 387 Pages
Global
From €3984EUR$4,197USD£3,361GBP
- Report
- November 2024
- 350 Pages
Global
From €3793EUR$3,995USD£3,199GBP
- Report
- December 2024
- 427 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- August 2024
- 112 Pages
Global
From €4414EUR$4,650USD£3,724GBP
- Report
- October 2024
- 191 Pages
Global
From €2326EUR$2,450USD£1,962GBP
- Report
- September 2024
- 154 Pages
Global
From €2136EUR$2,250USD£1,802GBP
- Report
- March 2025
- 194 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- March 2025
- 199 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 193 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 197 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 186 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 189 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 193 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP

The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments.
The iPS Cell market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting.
Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less Read more